Recent GLMD News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/09/2026 12:40:13 PM
- Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol • PR Newswire (US) • 04/09/2026 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/02/2026 04:15:10 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:36:15 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/31/2026 08:15:51 PM
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 • PR Newswire (US) • 03/31/2026 08:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 09:05:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 09:15:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/09/2026 09:15:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2026 09:20:03 PM
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 01/30/2026 09:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2025 01:39:37 PM
- Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting • PR Newswire (US) • 12/08/2025 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2025 01:42:40 PM
- Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update • IH Market News • 12/01/2025 04:40:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/01/2025 01:38:58 PM
- Galmed Issues CEO Letter to Shareholders • PR Newswire (US) • 12/01/2025 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/26/2025 01:57:00 PM
- Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update • PR Newswire (US) • 11/26/2025 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/18/2025 01:48:45 PM
- Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine • PR Newswire (US) • 11/18/2025 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/17/2025 01:39:34 PM
- Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro • PR Newswire (US) • 11/17/2025 01:30:00 PM
